Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers
Authors:
- Sandrine MorinSMSandrine Morin
- Annie RobertARAnnie Robert
- Marie Anne LoriotMLMarie Anne Loriot
- Philippe BeaunePBPhilippe Beaune
- Patrice JaillonPJPatrice Jaillon
- Laurent BecquemontLBLaurent Becquemont
- 1 November 2001
- journal article
- case report
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 11 (8) , 735-737
Abstract
Cytochrome P450 2C9 (CYP2C9) is the enzyme that terminates the anticoagulant effect of warfarin. The heterozygous carriers of the two allelic variants CYP2C9*2 and CYP2C9*3 have been associated with impaired warfarin metabolism and a higher risk of haemorrhage. Only three CYP2C9 poor metabolizers (CYP2C9*3/CYP2C9*3) initiating warfarin treatment have so far been identified, all of them with a dramatic overdose occurring a few days after treatment initiation. Acenocoumarol, another coumarinic anticoagulant, has recently been shown to be metabolized by CYP2C9. We report, for the first time, two cases of dramatic overanticoagulation occurring in patients starting acenocoumarol treatment while taking recommended doses (4 mg/day). In both cases, the overdose was discovered at the first INR control with values above 9. Genotyping revealed that the two patients were homozygous for the CYP2C9*3 allele. Our report highlights the need for CYP2C9 genotyping before starting oral anticoagulants in order to prevent early overanticoagulation episodes.Keywords
This publication has 9 references indexed in Scilit:
- The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarolPharmacogenetics, 2000
- Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatmentBlood, 2000
- Genetic Modulation of Oral Anticoagulation with WarfarinThrombosis and Haemostasis, 2000
- CYP2C9*3 allelic variant and bleeding complicationsThe Lancet, 1999
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Genetic association between sensitivity to warfarin and expression of CYP2C9*3Pharmacogenetics, 1997
- Genetic analysis of the human cytochrome P450 CYP2C9 locusPharmacogenetics, 1996
- The Incidence and Clinical Significance of Amiodarone and Acenocoumarol InteractionThrombosis and Haemostasis, 1989